Beranda › Leukemia Biphenotypic Akut › Colorado › Denver
Uji klinis Leukemia Biphenotypic Akut di Denver, CO
4 studi untuk Leukemia Biphenotypic Akut mencari peserta di lokasi sekitar Denver (dalam radius sekitar 30 mil). Buka studi untuk melihat kriteria peserta dan cara menghubungi tim studi.
Teks studi resmi (Bahasa Inggris)
Merekrut peserta untuk studi di sini? Tampilkan di bagian atas halaman ini — $99 selama 30 hari →
Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
Menerima pesertaFase 3
- Rocky Mountain Hospital for Children-Presbyterian Saint Luke's Medical Center, Denver
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
Menerima pesertaFase 1/2
- Rocky Mountain Hospital for Children-Presbyterian Saint Luke's Medical Center, Denver
Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
Menerima pesertaFase 1/2
- Colorado Blood Cancer Institute, Denver
Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
Menerima pesertaFase 1
- Children's Hospital Colorado, Denver
Uji klinis Leukemia Biphenotypic Akut di kota lain
- Seattle, WA15 studi
- Houston, TX11 studi
- New York City, NY10 studi
- Atlanta, GA9 studi
- Durham, NC8 studi
- Memphis, TN7 studi
- Chicago, IL7 studi
- Charlotte, NC6 studi
- Aurora, CO6 studi
- Baldwin Park, CA6 studi
- Portland, OR6 studi
- Los Angeles, CA6 studi
Studi lain di Denver
- Kanker Metastatik29 studi
- Kanker Payudara28 studi
- Mieloma Multipel27 studi
- Kanker Paru Non-Sel Kecil27 studi
- Kanker Kolorektal23 studi
- Kanker Prostat19 studi
- Melanoma19 studi
- Kanker (semua jenis)18 studi
- Kanker Ovarium16 studi
- Kanker Paru16 studi
- Kanker Endometrium15 studi
- Limfoma Non-Hodgkin14 studi
Dari ClinicalTrials.gov, data diambil 5 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.